Soulpower Acquisition Corp. SOUL
otherwise stated in this annual report or the context otherwise requires, references to:
window" are to (i) the period ending on the date that is 24 months from the closing
of our initial public offering, of such earlier liquidation date as our board of directors
may approve, in which we must complete an initial business combination or (ii) such other
Last close
10.46
2026-09-02
Market cap
$268.0M
2025-12-31 share count
52-week range
10.02 - 11.00
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| SG&A | $1.7M | — |
| Total operating expenses | $1.7M | — |
| Interest expense | $100.0K | — |
| Net income | $6.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Total current assets | $1.5M | $100.5K |
| Total assets | $259.1M | $100.5K |
| Accounts payable | $695.9K | $43.1K |
| Total current liabilities | $1.7M | $166.4K |
| Total liabilities | $12.3M | $166.4K |
| Retained earnings | -$10.8M | -$90.8K |
| Total equity | -$10.8M | -$65.8K |
Cash flow
| Fiscal year | FY2025 | FY2024 |
|---|---|---|
| Operating cash flow | -$2.3M | — |
| Investing cash flow | -$250.0M | — |
| Financing cash flow | $252.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013246.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $647.8M | — | — |
| IACO | Idea Acquisition Corp. | $437.1M | — | — |
| KRAQ | KRAKacquisition Corp | $431.6M | — | — |
| TACO | Berto Acquisition Corp. | $393.6M | 36.2x | — |
| ALDF | Aldel Financial II Inc. | $322.7M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $315.1M | — | — |
| FGII | FG Imperii Acquisition Corp. | $289.7M | — | — |
| DMAA | Drugs Made In America Acquisition Corp. | $261.2M | — | — |